<DOC>
	<DOCNO>NCT03066180</DOCNO>
	<brief_summary>This prospective , pilot clinical study involve two study group . This study design demonstrate study treatment meet primary efficacy safety endpoint . The treatment involve radiofrequency treatment address symptom stress urinary incontinence . After receive study treatment , subject follow 12 month post-treatment . At Screening Visit , designate follow-up timepoint , subject ask complete variety questionnaire , provide patient diary , undergo objective assessment urine loss .</brief_summary>
	<brief_title>Study Non-Ablative Radiofrequency Treatment Stress Urinary Incontinence</brief_title>
	<detailed_description>This prospective , pilot clinical study involve two study group . Subjects meet inclusion criterion none exclusion criterion enrol study . Subjects receive single SUI treatment ; subject Group 2 receive two SUI Treatments . At Screening Visit , pre-designated study follow-up timepoint , subject ask complete several quality life questionnaire relate treated condition . In addition , subject provide bladder void diary review data collection , pad weight test conduct result collect .</detailed_description>
	<mesh_term>Urinary Incontinence</mesh_term>
	<mesh_term>Enuresis</mesh_term>
	<mesh_term>Urinary Incontinence , Stress</mesh_term>
	<criteria>Able understand voluntarily sign date informed consent form ( ICF ) prior initiation screen studyspecific procedure . Willing comply study requirement instruction . Female , â‰¥ 18 year age . Normal pelvic exam Screening . Negative pregnancy test Screening . Diagnosed mild moderate Stress Urinary Incontinence ( SUI ) 1hour pad weight test ( `` mild '' define 1 10 g ; `` moderate '' define 11 50 g ; `` severe '' define &gt; 50 g ) Screening . Subject currently breastfeed discontinue breast feed few 6 month prior enrollment . Any condition , illness , surgery might confound result urinary incontinence assessment , include , limited : Categories urinary incontinence category investigate . Prominent ( i.e. , great stage II define International Continence Society ) pelvic organ prolapse ( e.g. , cystocele , rectocele ) . Neurological disorder ( e.g. , multiple sclerosis , Parkinson 's disease ) . Spastic bladder . Concurrent infection ( e.g. , urinary tract infection [ UTI ] , cystitis , urethritis , active genital herpes flareup , active genital/pelvic infection ) . Vesicoureteral reflux . Bladder stone . Bladder tumor . Morbid obesity . Any underlying condition may pose unreasonable risk subject , : Coagulation abnormality . Abnormal kidney function . Uncontrolled diabetes . Has implantable electrical device [ e.g. , implantable pacemaker , automatic implantable cardioverterdefibrillator ( AICD ) ] could potentially affect use radiofrequency . Taking new medication ( &lt; 3 month ) affect urination , change dosage medication affect urination within past 3 month . Medical history keloid formation , genital fistula , thin rectovaginal septum ( define distance &lt; 2 cm vaginal opening anal opening , measure flexible tape measure ) ; history fourthdegree laceration , hypertrophic scar formation , mediolateral episiotomy . Active malignancy undergo treatment ( use chemotherapeutic agent , radiation therapy , and/or cytostatic medication ) may interfere adequate wound heal response . Previous vaginal , energybased device treatment vaginal laxity , urinary incontinence , sexual function ( e.g. , radiofrequency treatment , cosmetic , laser , surgical , and/or genital enhancement procedure ) . Chronic use antiinflammatory drug , include ibuprofen , aspirin , steroid . Subject another clinical study within 6 month screen , willing abstain participate clinical study duration trial .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>